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Conclusions: OxyLDL leads to impaired NO generation and
apoptotic cell death in BAEC. This effect occurs via overexpression
of LOX-1 and the subsequent attenuation of protective autophagic
response thereby contributing in the pathophysiology of oxyLDL-
induced endothelial dysfunction which characterizes early stages of
atherosclerotic process.
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Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one
of the scavenger receptors for oxidized low density lipoprotein (ox-LDL),
plays a crucial role in signaling pathways involved in the process of
oxidative stress and inﬂammation. As evidence supporting the vital role
of LOX-1 keeps accumulating, there is growing interest in LOX-1 as a
potential therapeutic target. Here, we review the discovery and genetics
of LOX-1, describe existing evidence supporting the role of LOX-1 in
atherogenesis and its major complication- myocardial ischemia, and
summarize its modulation by some naturally occurring compounds that
could be of therapeutic use.
Ox-LDL/LOX-1 relationship appears to be an important player in
the development of atherosclerosis and its sequelae, such as MI and
cardiac remodeling. The scavenger receptor LOX-1 activates most, if
not all, signaling from the beginning to culmination of major life-
threatening events related to this malady. From genetic studies, it is
quite evident that certain individuals have propensity to develop
CAD-related events. Since the current therapies of coronary heart
disease, mainly LDL-cholesterol lowering drugs, are ineffective in a
large number of patients, there is need for new targets that focus on
the underlying signals of the disease process. A host of strategies are
being proposed that would either block oxidation of LDL-cholesterol
and/or reduce the expression of LOX-1. While the development of
these strategies is eagerly awaited, some naturally occurring
compounds appear quite promising and deserve clinical trials.
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The endothelium regulates vascular homoeostasis through local
elaboration of mediators that modulate vascular tone, platelet
adhesion, inﬂammation, ﬁbrinolysis, and vascular growth. Impaired
vascular function contributes to the pathogenesis of atherosclerosis
and acute coronary syndromes. Impaired endothelial function is
associated with atherothrombotic risk factors and atherothrombotic
disease, is pathophysiologically linked to acute cardiovascular
syndromes. A central feature of impaired endothelial function in
the presence of cardiac risk factors and under pathological conditions
is impairment in endothelium-derived bioactivity.
Nitric oxide is produced in endothelial cells from the conversion
of l-arginine to l-citrulline through the activity of (endothelial) nitric
oxide synthase. EDNO regulates vascular tone through a dilator
action on vascular smooth muscle cells that depends on soluble
guanylyl cyclase activation and consequent increase in guanosine
monophosphate. Additional antiatherogenic functions of EDNO relate
to inhibition of platelet activity, leucocyte adhesion, and vascular
smooth muscle cell proliferation. Mechanisms underlying impaired
endothelial function in various disease states such as hypertension,
diabetes mellitus, hypercholesterolaemia, and atherosclerosis are
likely multifactorial. There is growing evidence that oxidative stress
(deﬁned as an imbalance between endogenous oxidants and
antioxidants in favour of the former) contributes to mechanisms of
vascular dysfunction. These observations ﬁt well with the recogni-
tion that increased oxidative stress may be central to the atherogenic
process.
Although the mechanism of oxidative modiﬁcation of LDL
remains unknown, the importance of oxidation can be seen by the
presence of oxidized LDL in atherosclerotic lesions. Experimentally,
the amount of oxidized LDL is reﬂective of the atherosclerotic
burden. Oxidized LDL induces a series of atherogenic processes,
including transcription of proatherogenic genes, production of
matrix metalloproteinases and tissue factor, antagonism of endothe-
lial cell production of NO, and promotion of vascular smooth muscle
cell apoptosis. The augmented production of superoxide anion also
rapidly reacts with NO to produce peroxynitrite, a potent oxidant.
However, large trials of antioxidant vitamins, including the
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto
miocardico (GISSI) Prevention Trial, the Heart Outcomes Prevention
Evaluation Study (HOPE), and the Heart Protection Study (HPS),
have not demonstrated any reduction in clinical events with
antioxidant vitamin E therapy. The antioxidants used in these trials,
however, have limitations that may have precluded an adequate test
of the hypothesis. Conventional antiplatelet therapy has also
antioxidant effects by virtue of its ability to limit production of ROS
by activated platelets. The importance of oxidative stress in the
pathogenesis of atherosclerosis makes clear that the limitations of
current therapies should not conclude therapeutic interest in this
area but foster investigation into new avenues of treatment.
There is considerable need for additional investigation into the
basic mechanisms of atherosclerosis. It is important to clarify the
differential role of HDL cholesterol metabolism and other lipid
disturbances as well as the biomechanical and rheologic factors in
development and progression of disease in the noncoronary
circulations. Greater research is needed in understanding regional
differences in plaque formation and clinical manifestations of
disease. Genetic variability across individuals and populations merits
additional exploration using genomics and proteomics. Pathophysi-
ological responses to changes in metabolic demand such as exercise
and factors that determine development of collateral vessels and
angiogenesis need greater attention. In particular, the interaction
between reduced oxygen and substrate delivery and skeletal muscle,
neurological, and metabolic function needs additional study. There is
a need for improved functional imaging and biomarkers of disease
progression and unstable patterns of atherosclerosis to assist in
understanding of regional disease pathophysiology.
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